\-\ Texto\\:\\ \ \(0\)\
\-\ abdomen\\:\\ non\\-distended\\,\\ nabs\\ without\\ bruits\\.\\ \\ no\\ tenderness\\ to\\ palpation\\.\\ \\ no\\ guarding\\ or\\ rebound\\.\\ \ \(0\)\
\-\ back\\:\\ mild\\ right\\ cva\\ tenderness\\.\\ \ \(0\)\
\-\ creat\\ 2\\.4\ \(0\)\
\-\ multiple\\ axial\\ ct\\ views\\ of\\ the\\ abdomen\\ without\\ contrast\\ demonstrating\\ an\\ enlarged\\ right\\ kidney\\ with\\ loss\\ of\\ intrapelvic\\ \\ fat\\,\\ right\\-sided\\ dilation\\ of\\ collecting\\ system\\ with\\ proximal\\ right\\ ureteral\\ dilatation\\.\\ \\ no\\ evidence\\ of\\ radiopaque\\ stone\\ in\\ bilateral\\ ureters\\.\\ \\ small\\ stone\\ in\\ right\\ collecting\\ system\\.\ \(0\)\
\-\ right\\ hydronephrosis\ \(4\)\
\-\ left\\-sided\\ hydronephrosis\ \(2\)\
\-\ radiolucent\\ stone\\ secondary\\ to\\ protease\\ inhibitor\\ therapy\ \(1\)\
\-\ radiopaque\\ stone\\ undetected\\ on\\ ct\ \(0\)\
\-\ obstruction\\ secondary\\ to\\ neoplasm\ \(1\)\
\-\ 59\\ year\\-old\\ hiv\\ positive\\ male\\,\\ on\\ haart\\,\\ presenting\\ with\\ 4\\ day\\ history\\ of\\ right\\ flank\\ and\\ abdominal\\ pain\\.\\ \\ history\\ of\\ nephrolithiasis\\ since\\ beginning\\ protease\\ inhibitor\\ therapy\\.\ \(0\)\
\-\ protease\\ inhibitor\\ associated\\ nephrolithiasis\\ is\\ classically\\ seen\\ with\\ indinavir\\,\\ in\\ which\\ 10\\-25\\%\\ of\\ adult\\ patients\\ taking\\ the\\ drug\\ can\\ develop\\ stones\\.\\ \\ the\\ stones\\ are\\ classically\\ radiolucent\\ on\\ ct\\.\\ \\ given\\ the\\ poor\\ kidney\\ function\\ in\\ this\\ patient\\,\\ intravenous\\ contrast\\ was\\ unable\\ to\\ be\\ administered\\.\\ \\ however\\,\\ such\\ a\\ study\\ would\\ be\\ effective\\ in\\ evaluating\\ for\\ a\\ filling\\ defect\\ within\\ the\\ right\\ ureter\\ as\\ a\\ cause\\ of\\ the\\ hydronephrosis\\.\\ \\ other\\ options\\ for\\ further\\ radiological\\ evaluation\\ would\\ include\\ intravenous\\ pyelogram\\ and\\ retrograde\\ pyelography\\.\\ \\ however\\,\\ due\\ to\\ decreased\\ renal\\ function\\,\\ no\\ additional\\ studies\\ were\\ obtained\\,\\ and\\ the\\ case\\ was\\ managed\\ as\\ a\\ presumed\\ stone\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ protease\\:\\ 0\\.33847607327202855\ \(0\)\
\-\ stone\\:\\ 0\\.32221149983801056\ \(0\)\
\-\ inhibitor\\:\\ 0\\.25907244140281105\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.19642063723382558\ \(0\)\
\-\ right\\:\\ 0\\.18712286301146114\ \(0\)\
\-\ radiopaque\\:\\ 0\\.16996373154633537\ \(0\)\
\-\ radiolucent\\:\\ 0\\.15415572501893351\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.1480924815072685\ \(0\)\
\-\ classically\\:\\ 0\\.1475605132808035\ \(0\)\
\-\ stones\\:\\ 0\\.1331973302000098\ \(0\)\
\-\ collecting\\:\\ 0\\.13232932643214285\ \(0\)\
\-\ intravenous\\:\\ 0\\.12863847283828897\ \(0\)\
\-\ function\\:\\ 0\\.11420832272341652\ \(0\)\
\-\ intrapelvic\\:\\ 0\\.11282535775734286\ \(0\)\
\-\ indinavir\\:\\ 0\\.11282535775734286\ \(0\)\
\-\ of\\:\\ 0\\.11045111927193003\ \(0\)\
\-\ haart\\:\\ 0\\.10781065264694341\ \(0\)\
\-\ system\\:\\ 0\\.10764511607834597\ \(0\)\
\-\ pyelogram\\:\\ 0\\.10149287137601108\ \(0\)\
\-\ pyelography\\:\\ 0\\.10149287137601108\ \(0\)\
\-\ would\\:\\ 0\\.09988258694880557\ \(0\)\
\-\ kidney\\:\\ 0\\.09912839532047725\ \(0\)\
\-\ the\\:\\ 0\\.098541448967425\ \(0\)\
\-\ undetected\\:\\ 0\\.09567996773929141\ \(0\)\
\-\ no\\:\\ 0\\.09176867544473227\ \(0\)\
\-\ nabs\\:\\ 0\\.09174140059521084\ \(0\)\
\-\ creat\\:\\ 0\\.08967531166345988\ \(0\)\
\-\ tenderness\\:\\ 0\\.08848759537027406\ \(0\)\
\-\ to\\:\\ 0\\.08818723618814697\ \(0\)\
\-\ in\\:\\ 0\\.08775317879427096\ \(0\)\
\-\ abdomen\\:\\ 0\\.08609493300585021\ \(0\)\
\-\ bruits\\:\\ 0\\.08374405511805637\ \(0\)\
\-\ secondary\\:\\ 0\\.08363393514810971\ \(0\)\
\-\ however\\:\\ 0\\.08351510912702875\ \(0\)\
\-\ cva\\:\\ 0\\.08316870558618511\ \(0\)\
\-\ therapy\\:\\ 0\\.0810714957889682\ \(0\)\
\-\ ct\\:\\ 0\\.0805775342087071\ \(0\)\
\-\ beginning\\:\\ 0\\.07778478545857796\ \(0\)\
\-\ ureters\\:\\ 0\\.07673899789908901\ \(0\)\
\-\ retrograde\\:\\ 0\\.07546939343578336\ \(0\)\
\-\ without\\:\\ 0\\.0744253071750649\ \(0\)\
\-\ ureteral\\:\\ 0\\.07351987261084048\ \(0\)\
\-\ radiological\\:\\ 0\\.07326485770859452\ \(0\)\
\-\ administered\\:\\ 0\\.07301499497662785\ \(0\)\
\-\ effective\\:\\ 0\\.07206315739906728\ \(0\)\
\-\ presumed\\:\\ 0\\.07206315739906728\ \(0\)\
\-\ evaluating\\:\\ 0\\.07096794805722445\ \(0\)\
\-\ hiv\\:\\ 0\\.06977013027310236\ \(0\)\
\-\ ureter\\:\\ 0\\.06921209044955223\ \(0\)\
\-\ guarding\\:\\ 0\\.06903153564323478\ \(0\)\
\-\ managed\\:\\ 0\\.06903153564323478\ \(0\)\
\-\ contrast\\:\\ 0\\.06855794268513586\ \(0\)\
\-\ taking\\:\\ 0\\.06833457466371298\ \(0\)\
\-\ rebound\\:\\ 0\\.06720209133990816\ \(0\)\
\-\ 59\\:\\ 0\\.06689669842675763\ \(0\)\
\-\ adult\\:\\ 0\\.06507668438281018\ \(0\)\
\-\ develop\\:\\ 0\\.06494717760181476\ \(0\)\
\-\ drug\\:\\ 0\\.06419738533915276\ \(0\)\
\-\ on\\:\\ 0\\.06392224394238101\ \(0\)\
\-\ options\\:\\ 0\\.06360551237853576\ \(0\)\
\-\ dilation\\:\\ 0\\.06208474842405308\ \(0\)\
\-\ flank\\:\\ 0\\.061881993316358165\ \(0\)\
\-\ unable\\:\\ 0\\.06110266250472173\ \(0\)\
\-\ poor\\:\\ 0\\.059510322821686966\ \(0\)\
\-\ demonstrating\\:\\ 0\\.05817408904189286\ \(0\)\
\-\ dilatation\\:\\ 0\\.05759196820704568\ \(0\)\
\-\ be\\:\\ 0\\.0572389076381093\ \(0\)\
\-\ as\\:\\ 0\\.05668515350712476\ \(0\)\
\-\ views\\:\\ 0\\.05568546580660958\ \(0\)\
\-\ presenting\\:\\ 0\\.05526617871867313\ \(0\)\
\-\ with\\:\\ 0\\.055258556894687984\ \(0\)\
\-\ additional\\:\\ 0\\.05469082918680187\ \(0\)\
\-\ filling\\:\\ 0\\.05463473936469496\ \(0\)\
\-\ history\\:\\ 0\\.05390863068624957\ \(0\)\
\-\ defect\\:\\ 0\\.051752438543730954\ \(0\)\
\-\ studies\\:\\ 0\\.051752438543730954\ \(0\)\
\-\ since\\:\\ 0\\.05110476258014359\ \(0\)\
\-\ obtained\\:\\ 0\\.049903062270616354\ \(0\)\
\-\ was\\:\\ 0\\.049174986227659055\ \(0\)\
\-\ given\\:\\ 0\\.04853146635268253\ \(0\)\
\-\ neoplasm\\:\\ 0\\.048161246518918524\ \(0\)\
\-\ enlarged\\:\\ 0\\.04809510847587087\ \(0\)\
\-\ cause\\:\\ 0\\.048062171613324566\ \(0\)\
\-\ palpation\\:\\ 0\\.04757836346389506\ \(0\)\
\-\ back\\:\\ 0\\.047051995321101305\ \(0\)\
\-\ study\\:\\ 0\\.047051995321101305\ \(0\)\
\-\ positive\\:\\ 0\\.04648905286391366\ \(0\)\
\-\ further\\:\\ 0\\.04595062211938676\ \(0\)\
\-\ such\\:\\ 0\\.04538157657081962\ \(0\)\
\-\ day\\:\\ 0\\.04493935840600162\ \(0\)\
\-\ proximal\\:\\ 0\\.04407585234592025\ \(0\)\
\-\ renal\\:\\ 0\\.04393369233734134\ \(0\)\
\-\ fat\\:\\ 0\\.043886666483816436\ \(0\)\
\-\ and\\:\\ 0\\.043735094081669264\ \(0\)\
\-\ decreased\\:\\ 0\\.04370033098817825\ \(0\)\
\-\ evaluation\\:\\ 0\\.04302555722425213\ \(0\)\
\-\ loss\\:\\ 0\\.04298185475978078\ \(0\)\
\-\ for\\:\\ 0\\.0427665351930428\ \(0\)\
\-\ include\\:\\ 0\\.04197681192600065\ \(0\)\
\-\ axial\\:\\ 0\\.040752415355259156\ \(0\)\
\-\ due\\:\\ 0\\.04055365924385154\ \(0\)\
\-\ evidence\\:\\ 0\\.04004448051949763\ \(0\)\
\-\ mild\\:\\ 0\\.039992983770941064\ \(0\)\
\-\ patients\\:\\ 0\\.039688426490680044\ \(0\)\
\-\ abdominal\\:\\ 0\\.03858585419212508\ \(0\)\
\-\ bilateral\\:\\ 0\\.03791635785488793\ \(0\)\
\-\ associated\\:\\ 0\\.037185321455797386\ \(0\)\
\-\ can\\:\\ 0\\.037022585100302374\ \(0\)\
\-\ other\\:\\ 0\\.03663792594300648\ \(0\)\
\-\ small\\:\\ 0\\.03639224310532201\ \(0\)\
\-\ were\\:\\ 0\\.03636666339697589\ \(0\)\
\-\ case\\:\\ 0\\.035443725292799926\ \(0\)\
\-\ multiple\\:\\ 0\\.03450770835644568\ \(0\)\
\-\ seen\\:\\ 0\\.03321453038337718\ \(0\)\
\-\ within\\:\\ 0\\.03249331259386638\ \(0\)\
\-\ which\\:\\ 0\\.03207994303180942\ \(0\)\
\-\ male\\:\\ 0\\.03141172677848126\ \(0\)\
\-\ an\\:\\ 0\\.026978214451192542\ \(0\)\
\-\ are\\:\\ 0\\.02677064666379104\ \(0\)\
\-\ pain\\:\\ 0\\.025245509170466786\ \(0\)\
\-\ or\\:\\ 0\\.024543208180423368\ \(0\)\
\-\ this\\:\\ 0\\.024242368458247534\ \(0\)\
\-\ patient\\:\\ 0\\.022946484961236146\ \(0\)\
\-\ is\\:\\ 0\\.019320690826445816\ \(0\)\
